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Sevoflurane ameliorates gas exchange and attenuates lung
damage in experimental lipopolysaccharide-induced lung injury
Abstract
BACKGROUND: Acute lung injury is a common complication in critically ill patients. Several studies
suggest that volatile anesthetics have immunomodulating effects. The aim of the current study was to
assess possible postconditioning with sevoflurane in an in vivo model of endotoxin-induced lung injury.
METHODS: Rats were anesthetized, tracheotomized, and mechanically ventilated. Lipopolysaccharide
(saline as control) was administered intratracheally. Upon injury after 2 h of propofol anesthesia, general
anesthesia was continued with either sevoflurane or propofol for 4 h. Arterial blood gases were
measured every 2 h. After 6 h of injury, bronchoalveolar lavage was performed and lungs were
collected. Total cell count, albumin content, concentrations of the cytokines cytokine-induced neutrophil
chemoattractant-1 and monocyte chemoattractant protein-1, and phospholipids were analyzed in
bronchoalveolar lavage fluid. Expression of messenger RNA for the two cytokines and for surfactant
protein B was determined in lung tissue. Histopathologic examination of the lung was performed.
RESULTS: Significant improvement of the ratio of oxygen tension to inspired oxygen fraction was
shown with sevoflurane (mean + or - SD: 243 + or - 94 mmHg [32.4 kPa]) compared with propofol (88
+ or - 19 mmHg [11.7 kPa]). Total cell count representing effector cell recruitment as well as albumin
content as a measure of lung permeability were significantly decreased in the
sevoflurane-lipopolysaccharide group compared with the propofol-lipopolysaccharide group in
bronchoalveolar lavage fluid. Expression of the cytokines protein in bronchoalveolar lavage fluid as
well as messenger RNA in lung tissue was significantly lower in the sevoflurane-lipopolysaccharide
group compared with the propofol-lipopolysaccharide group. CONCLUSIONS: Postconditioning with
sevoflurane attenuates lung damage and preserves lung function in an in vivo model of acute lung
injury.
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ABSTRACT  
Background: Acute lung injury is a common complication in critically ill patients. Several 
studies suggest that volatile anesthetics have immunomodulating effects. The aim of the 
present study was to assess a possible postconditioning with sevoflurane in an in vivo model 
of endotoxin-induced lung injury.  
Material and Methods: Rats were anesthetized, tracheotomized and mechanically ventilated. 
Lipopolysaccharide (saline as control) was administered intratracheally. Upon injury after two 
hours of propofol anesthesia, general anesthesia was continued with either sevoflurane or 
propofol for four hours. Arterial blood gases were measured every two hours. After six hours 
of injury bronchoalveolar lavage was performed and lungs were collected. Total cell count, 
albumin content, and concentrations of the cytokines cytokine-induced neutrophil 
chemoattractant-1, monocyte chemoattractant protein-1 and phospholipids were analysed in 
bronchoalveolar lavage fluid. Expression of messenger RNA for the two cytokines and for 
surfactant protein b was determined in lung tissue. Histopathological examination of the lung 
was performed. 
Results: A significant improvement of PaO2/FiO2 was shown with sevoflurane (243 ± 94 torr 
[32.4 kPa]) compared to propofol (88 ± 19 torr [11.7 kPa]) [mean ± SD]. Total cell count as a 
measure of effector cell recruitment and albumin content as a measure of lung permeability 
were significantly decreased in the sevoflurane-lipopolysaccharide group compared to the 
propofol-lipopolysaccharide group in bronchoalveolar lavage fluid. Expression of the 
cytokines protein in bronchoalveolar lavage fluid as well as messenger RNA in lung tissue 
was significantly lower in the sevoflurane-lipopolysaccharide group compared to the 
propofol-lipopolysaccharide group. 
Conclusions: We conclude that postconditioning with sevoflurane attenuates lung damage 
and preserves lung function in an in vivo model of acute lung injury.
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INTRODUCTION 
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are a common 
finding in today’s intensive care units (ICU) 1. Despite the introduction of new therapeutic 
approaches, mortality in patients with ARDS could not be improved substantially since its 
first description 2 and remains high (30-40%) 1,3. To date, only low tidal volume ventilation 
has been shown to positively influence mortality in ARDS 4.  
Patients on ICUs who need mechanical ventilation due to ALI/ARDS are often sedated using 
intravenous sedatives like propofol or midazolam 5. Only recently it has become feasible to 
sedate patients with volatile anesthetics using the Anaesthetic Conserving Device 
(AnaConDa) (Sedana Medical AB, Sundbyberg, Sweden). 
Apart from many direct advantages compared to intravenous drugs 6, volatile 
anesthetics have been shown to possess antiinflammatory properties 7-9. Furthermore, recent 
studies suggest that sevoflurane might act as a pre-and postconditioning agent 10 inducing 
organ protection in models of ALI due to inhibition of the expression of proinflammatory 
mediators. The knowledge about the immunomodulatory effects of volatile anesthetics 
mainly originates from ischemia-reperfusion injury studies. Administration of volatile 
anesthetics prior to ischemia, called anesthetic preconditioning, has been shown to attenuate 
ischemia-reperfusion induced injury in the heart 11,12, the kidney 13, the lung 14,15 and in the 
liver 9. While preconditioning seems to be an efficient approach, the possibility of 
postconditioning would be even more interesting and expand the clinical applicability, as it is 
not tied to a specific time point. In fact, the administration of volatile anesthetics after the 
onset of lung injury could be readily applied to many clinical scenarios in the operating room 
and even later in the intensive care unit. 
Based on our previous in vitro data we hypothesized that postconditioning with 
sevoflurane might attenuate the inflammatory reaction in an in vivo model of endotoxin-
induced lung injury.
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MATERIAL AND METHODS 
Animal preparation  
After approval obtained from the local animal care and use committee (Zurich, Switzerland), 
pathogen-free, male Wistar rats weighing 350 – 500 g (Charles River, Sulzfeld, Germany) 
were used. The rats were housed in standard cages at 22 ± 1°C temperature under a 12/12-hr 
light/dark regimen. Food and water were supplied ad libitum. 
Rats were anesthetized with intraperitoneal sodium thiopenthal (100 mg/kg; Pentothal, 
Swissmedic, Ospedalia AG, Hünenberg, Switzerland). For continuous propofol infusion and 
fluid administration (sodium chloride 10 ml/kg/hour) the tail vein was cannulated with a 
sterile 22 GA catheter (BD Insyte, Becton Dickinson S.A., Madrid, Spain). A sterile 
polyethylene catheter for blood sampling and blood pressure monitoring was placed into the 
left carotid artery (pressure transducer, Spacelabs, Hertford, United Kingdom). The rats were 
tracheotomized and a sterile metal cannula was inserted into the trachea followed by 
mechanical ventilation in pressure-controlled modus (Servo Ventilator 300, Maquet, Solna, 
Sweden). Peak inspiratory pressure (PIP) was 14 cmH2O with a positive end-expiratory 
pressure (PEEP) of 3 cmH2O. The fractional inspired oxygen concentration (FiO2) was 1.0, 
I/E ratio was 1:2; respiratory frequency = 30 min−1. Arterial blood samples were analyzed at 
0, 2, 4, and 6 hours for PaO2 and PaCO2. Body temperature was maintained at 37°C by a 
warming lamp. 
To evaluate the oxygenation capability of the lung over time, the ratio of oxygen 
tension to inspired oxygen fraction (PaO2/FiO2) was calculated at defined time points for each 
group (0, 2, 4, 6 hours) as well as alveolo-arterial oxygen tension difference with values 
obtained from Federal Office of Meteorology and Climatology MeteoSwiss.  
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Experimental Design  
Rats were randomized into four different groups: 1. propofol-lipopolysaccharide (n=6), 2. 
propofol-phosphate-buffered saline (PBS) (n=4), 3. sevoflurane-lipopolysaccharide (n=6) 4. 
sevoflurane-PBS (n=4). Rats in the lipopolysaccharide-groups were intratracheally instilled 
with 150 μg of Escherichia coli-lipopolysaccharide (serotype 055:B5) (Sigma Aldrich, 
Buchs, Switzerland) in 300 μl PBS 16. Both control groups (propofol-PBS and sevoflurane-
PBS) received 300 μl intratracheally instilled PBS. After the application of either 
lipopolysaccharide or PBS rats were ventilated as described and propofol was infused 
intravenously at a dose of 10-20 mg/kg/h to maintain anesthesia. Propofol 97% (Sigma 
Aldrich, Buchs, Switzerland) was dissolved in a 14% Cremophor® EL (Biochemika Fluka, 
Buchs, Switzerland) solution to a final concentration of 10 mg/ml 17. Two hours after the 
onset of lung injury the anesthetic was changed according to the protocol to either propofol 
or sevoflurane for subsequent 4 hours (6 hour injury model with 4 hours of 
postconditioning). Sevoflurane was administered using the AnaConDa-system. The 
expiratory concentration of sevoflurane was measured with a multigas analyzer (VEO 
Multigas Monitor, PHASEIN Medical Technologies, Danderyd, Sweden). In all experiments, 
concentration of sevoflurane was 1-2 Vol. %, respectively 0.5 -1 minimal alveolar 
concentration (MAC).  
Preparation and analysis of samples  
At the end of the experiment, animals were euthanized. The right heart was flushed with 10 
ml PBS, after which a bronchoalveolar lavage was performed (3 x 10 ml PBS, pooled). The 
collected fluid was centrifuged at 4°C (1.500 x g for 10 min) and aliquots of the supernatant 
were frozen at -20°C. The cell pellet was re-suspended in 1 ml PBS. After dying the cells with 
trypan blue cells were counted with a Neubauer chamber. 
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Finally, lungs were shock-frozen in liquid nitrogen and stored at -80°C for isolation of 
RNA. 
 
Measurement of lung permeability 
To assess the differences in lung permeability between the study groups total protein and 
albumin were measured in bronchoalveolar lavage fluid (BALF). Total protein was 
determined using a Bradford assay (Bio-Rad, Hercules, CA). Albumin levels were assessed 
using an ELISA assay (Bethyl Laboratories Inc., Montgomery, TX) according to the 
manufacturer’s protocol. The detection range for albumin was 7.8-10000 ng ml-1.  
 
ELISA (Enzyme-linked immunosorbent assay) 
Sandwich ELISAs were performed according to the manufacturer’s protocol assessing the 
chemokines cytokine-induced neutrophil chemoattractant-1 (CINC-1) (R&D Systems Europe 
Ltd, Abingdon, United Kingdom) and monocyte chemoattractant protein-1 (MCP-1) (BD 
Biosiences, San Diego, CA). The detection range for CINC-1 protein was 7.8-1000 pg ml-1 
and 62.5-16000 pg ml-1 for MCP-1.  
 
RNA extraction and real-time PCR for CINC-1 and MCP-1  
Total RNA was isolated from lung tissue using the RNeasy Mini Kit (Qiagen, Basel, 
Switzerland) according to the manufacturer’s protocol. Tissue was lysed in the provided 
buffer and subsequently loaded on RNeasy mini spin columns. RNA was eluted with RNAse-
free water. Total amounts and purity of RNA were determined by absorbance at 260 nm and 
the 260/280 nm absorbance-ratio, respectively. 
Reverse transcription was performed with 0.8 μg total RNA at 20°C for 5 min, 42°C 
for 30 min and 95°C for 5 min. Random hexanucleotide primers and murine leukaemia virus 
reverse transcriptase were used for cDNA synthesis. 
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Real time quantitative TaqMan PCR was performed on a GeneAmp 5700 system (P.E. 
Applied Biosystems, Waltham, MA). Specific primers (Microsynth, Balgach, Switzerland) 
and labeled TaqMan probes (Roche Applied Science, Basel, Switzerland) were designed for 
MCP-1, CINC-1, and 18S. The TaqMan universal PCR Master Mix (Applied Biosystems, 
Branchburg, N.J.) was used for the assays in a final reaction volume of 15 µl. All primers and 
probes used in the experiments are presented in table 1. Each experimental PCR run was 
performed in duplicate with simultaneous assays for controls with no template. 
For quantitation of gene expression the comparative Ct method was used as described 
by Livak et. al 18. The Ct values of samples (propofol-LPS and sevoflurane-LPS) and controls 
(propofol-PBS and sevoflurane-PBS) were normalized to the housekeeping gene (18S) and 
calculated as follows: 2-[delta] [delta] Ct where [delta][delta]Ct = [delta]Ct, samples  - [delta]Ct, controls. 
 
Histopathological Analysis 
For histological examination lungs (previously not flushed in the respiratory compartment) 
were fixed with 3% paraformaldehyde in PBS and then imbedded in TissueTek (Sakura 
Finetec Inc., Torrance, CA, USA). A series of microsections (7 µm) of every study group was 
stained with hematoxylin and eosin. Lung injury was quantified by 3 blinded researchers, 
using a lung injury score described previously 19,20. The lung pathology was assed by various 
degrees of edema (0 = no, 1 = mild, 2 = moderate, 3 = severe) and reactive cell infiltration (0 
= no, 1 = mild, 2 = moderate, 3 = severe). Adding these two individual scores resulted in the 
final score ranging from 0 to 6. 
 
Isolation of Surfactant and Phospholipid Assay 
Surfactant was pelleted by high-speed centrifugation (30,000 g for 45 min at 4°C). The crude 
pellet was resuspended in 110 μl of 0.9% saline, and total phospholipid content was measured 
using the method of Stewart21. Fifty microliters of sample were added to glass tubes 
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containing 2 ml of spectroscopic-grade chloroform. Two milliliters of 3.04% (wt/vol) 
ammonium ferrocyanate and 2.7% (wt/vol) ferric chloride hexahydrate in distilled H2O were 
added, and the mixture was vortexed for 1 min. Standards (0 – 100 mg/ml) were prepared 
with phosphatidylcholine in chloroform. The lower chloroform phase was withdrawn, and 
absorption was measured at 488 nm with a quartz cuvette. 
 
In vitro Experiments with Rat Pulmonary Artery Endothelial Cells (RPAEC) and Alveolar 
Epithelial Cells (AEC) 
RPAEC cell culture: The cell line, kindly provided by Dr Roscoe Warner PhD, Department of 
Pathology, University of Michigan, Ann Arbor, MI, was cultured in Dulbecco’s modified 
Eagle’s Medium (DMEM; Invitrogen AG, Basel, Switzerland), supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin-streptomycin, and 1% HEPES buffer in an incubator with 
5% CO2. They were grown in uncoated 35 x 10 mm plates (Corning Inc., Corning, NY) to 
more than 95% confluence. DMEM/10% FBS was replaced by DMEM/1% FBS 24 h before 
lipopolysaccharide stimulation. RPAEC were stimulated with lipopolysaccharide from 
Escherichia coli, serotype 055:B5 (Sigma, Buchs, Switzerland) in a concentration of 20 μg/l 
in DMEM/1% FBS for 6 hours (control group only stimulation with PBS in DMEM/1% FBS 
instead of lipopolysaccharide).  
AEC cell culture: The L2 cell line (CCL 149, American Type Culture Collection, 
Rockville, MD) was derived through cloning of adult female rat lung of AEC type II origin 22. 
The cells were cultured and stimulated in the same way as RPAEC.  
Hypercapnia: For the incubation time of 6 hours, the following CO2 concentrations were 
chosen: 5% (control), 7.5%, and 10%. Supernatants were collected and ELISA’s were 
performed and expression of CINC-1 and MCP-1 was analyzed. 
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Incubation with propofol: Control and stimulated RPAEC were exposed to propofol 
diluted in cremophor EL 14% for 6 hours. Supernatants were collected and ELISA’s were 
performed and expression of CINC-1 and MCP-1 was analyzed.  
For all experiments, cell viability was 95% as determined by measurement of 
lactatdehydrogenase (CytoTox 96, Non-Radioactive Cytotoxicity Assay, Promega, Madison, 
WI).   
 
Statistics 
Values were expressed as mean ± SD.  
PaO2/FiO2 ratio and alveolar–arterial oxygen tension difference (PO2 difference) data were 
tested by analysis of variances for repeated measurements (two-way ANOVA). The 
interaction testing between group and time from the repeated measures have been performed.  
ELISA data were tested by analysis of variances for repeated measurements (one-way 
ANOVA) with a Tukey-Kramer Multiple post-hoc test. Realtime PCR data were tested using 
a t-test with two-tailed hypothesis testing. Graphpad Prism4 and GraphPad Instat3 (GraphPad 
software, La Jolla, CA) were used for statistical analyses. P-values less or equal to 0.05 were 
considered statistically significant. 
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RESULTS   
Gas Exchange 
Intratracheal lipopolysaccharide resulted in a significant decrease of PaO2/FiO2 for both 
anesthetics (propofol and sevoflurane) compared to the PBS controls after 6 hours of injury 
(Fig.1A). Animals in the sevoflurane-lipopolysaccharide group had a significantly higher 
PaO2/FiO2 (243 ± 94 torr [32.4 kPa]) compared to the propofol-lipopolysaccharide (88 ± 19 
torr [11.7 kPa]) group after 6 hours of lipopolysaccharide injury. There were no significant 
differences between both PBS groups (sevoflurane-PBS, 415 ± 28 torr [55.3 kPa]; propofol-
PBS, 433 ± 32 torr [57.7 kPa]) (Fig. 1A). The influence of factor sevoflurane and time was 
p=0.0169 and p=0.0202, respectively. No significant interaction could be found between 
sevoflurane and time (p=0.3284). 
Accordingly, intratracheal lipopolysaccharide resulted in an increase of the alveolar–
arterial oxygen tension difference (PO2 difference) for both anesthetics. The propofol-
lipopolysaccharide group had a significantly higher PO2 difference compared to the 
sevoflurane-lipopolysaccharide group after 6 hours, whereas no differences were found in the 
PBS groups (Fig. 1B). 
PaCO2 levels were higher in both lipopolysaccharide groups compared with PBS 
groups. PaCO2 was significantly higher in the propofol-lipopolysaccharide group (56.6 ± 8.1 
torr [7.5 kPa]) compared with the sevoflurane-lipopolysaccharide group (42.2 ± 7.1 torr [5.6 
kPa]) after 6 hours of lipopolysaccharide injury (Tab. 2). 
 
Circulatory Variables 
Mean arterial pressure (MAP) decreased in all four study groups during the course of the 
experiment. There were no significant differences in MAP between the four groups at anytime 
(Tab. 2).  
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BALF Analysis 
The recovery of BALF was comparable in all study groups. 70% of administered fluid was 
retrieved. 
 
Total Cell Count  
Total cell count in BALF was determined as a measure of effector cell recruitment. While 
cells in BALF of PBS animals were identified as alveolar macrophages, 99.5% of the cells in 
lipopolysaccharide animals were neutrophils. Cell count increased significantly in both 
lipopolysaccharide groups compared to both control groups. The sevoflurane- 
lipopolysaccharide group showed a significantly lower total cell number compared to the 
propofol-lipopolysaccharide group (sevoflurane-LPS, 14.94 ± 5.72 cells/106 ml-1; propofol- 
lipopolysaccharide, 27.18 ± 7.75 cells/106 ml-1) (Fig. 2). There were no significant differences 
between the PBS groups. 
 
Albumin and Proteins 
Albumin concentration in BALF, reflecting alveolo-capillary permeability, was significantly 
lower in the sevoflurane-LPS group compared to the propofol-lipopolysaccharide group 
(sevoflurane-lipopolysaccharide, 4.9 ± 3.8 μg ml-1; propofol-lipopolysaccharide, 10.4 ± 3.5 μg 
ml-1) (Fig. 3). The alveolar protein content as a measure of accumulation of proteins upon 
inflammation was significantly higher in the lipopolysaccharide groups compared to the PBS 
groups. Additionally, a significantly lower protein concentration was found in the 
sevoflurane-lipopolysaccharide group compared to the propofol-lipopolysaccharide group 
(sevoflurane-lipopolysaccharide, 1.39 ± 0.51 mg ml-1; propofol-lipopolysaccharide, 2.26 ± 
0.32 mg ml-1) (Tab. 2). 
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Chemokine Analysis 
The protein concentration of the chemokines CINC-1 and MCP-1 in BALF was assessed by 
ELISA. CINC-1 and MCP-1 level increased significantly in both LPS groups compared with 
both PBS groups. The sevoflurane-lipopolysaccharide group showed significantly lower 
levels of CINC-1 and MCP-1 compared to the propofol- lipopolysaccharide group (Fig. 4A, 
4B). In the sevoflurane-lipopolysaccharide group CINC-1 and MCP-1 expression decreased 
29% and 53% respectively compared to the propofol-lipopolysaccharide group. 
  
Lung Tissue Analysis 
The expression of mRNA of CINC-1 and MCP-1 was analyzed in total lung tissue by real-
time PCR. Values were normalized to 18S and expressed relatively to controls (PBS groups). 
The mRNA expression in both LPS groups was significantly increased compared to both PBS 
groups. Again the sevoflurane-lipopolysaccharide group showed significantly lower mRNA 
levels compared to the propofol-lipopolysaccharide group (Fig. 5A, 5B): in the sevoflurane-
lipopolysaccharide group CINC-1 mRNA and MCP-1 mRNA expression decreased 42% and 
53% respectively compared to the propofol-lipopolysaccharide group. 
 
Histopathological Analysis 
As expected, intratracheal lipopolysaccharide resulted in a pulmonary edema with 
inflammatory cell recruitment (Fig. 6). Quantification of the injury showed a significant 
increase of the lung injury score in both lipopolysaccharide groups compared to the PBS 
groups. However, there was no significant difference between the sevoflurane- 
lipopolysaccharide group and the propofol- lipopolysaccharide group (Tab. 2). 
 
Alveolar Epithelial Cell Injury 
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Evalution of SP-B RNA expression in lung tissue revealed a decrease in the expression of SP-
B in both lipopolysaccharide groups compared to controls. However, decrease of SP-B in the 
sevoflurane-lipopolysaccharide animals was less accentuated compared to propofol- 
lipopolysaccharide animals (Fig. 7).  
Futhermore, analysis of the phospholipid content in BAL revealed an increase in the 
expression of phospholipids in both lipopolysaccharide groups compared to controls. 
Propofol-lipopolysaccharide showed significantly higher phospholipid levels compared to the 
sevo-lipopolysaccharide animals (Fig. 8).  
 
In vitro Experiments with Rat Pulmonary Artery endothelial and Alveolar Epithelial Cells 
As a significant higher PCO2 was observed in the lipopolysaccharide-propofol group after 6 
hours of injury, we analysed the possible pro-inflammatory effect of hypercapnia on RPAEC 
and AEC with or without lipopolysaccharide stimulation. CO2 values of 7.5% or 10% did not 
seem to have an impact on the inflammatory reaction in RPAEC or AEC compared to 5% 
CO2 (Fig. 9A and 9B). Similarly, we analyzed the possible pro-inflammatory effects of 
propofol in 14% cremophor. As AEC are not in direct contact with the anesthetic, we used 
smaller concentrations of propofol for the in vitro approach. No pro-inflammatory effects 
were shown in non-stimulated RPAEC or AEC. Stimulation with lipopolysaccharide in the 
presence of propofol resulted in the same increase of CINC-1 and MCP-1 levels as observed 
in the lipopolysaccharide group (Fig. 9C and 9D). 
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DISCUSSION 
The present study demonstrates that anesthetic postconditioning with sevoflurane improves 
oxygenation and attenuates lung damage as indicated by less recruitment of effector cells into 
the respiratory compartment, decreased expression of the proinflammatory mediators CINC-1 
and MCP-1, and reduced lung hyperpermeability in an in vivo model of lipopolysaccharide-
induced lung injury. 
These results corroborate our previous in vitro studies, where we showed a significant 
reduction of proinflammatory mediators by preconditioning 7 and by postconditioning 10 of 
alveolar epithelial cells (AEC) with sevoflurane in in vitro models of LPS-induced injury. 
This is the first in vivo study comparing the postconditioning effects of sevoflurane and 
propofol in a model of ALI.  
First, we focused on the effect of both anesthetics on oxygenation capability of the 
lung. The significant improvement of the arterial oxygen tension-to-inspired oxygen fraction 
(PaO2/FiO2) by postconditioning with sevoflurane after 6 hours is most likely due to a less 
impaired gas exchange compared to propofol sedation. This was also reflected in the 
calculations of alveolar–arterial oxygen tension difference. As discussed below the reason for 
this seems to be an attenuation of lung damage after lipopolysaccharide challenge. To our 
knowledge the amelioration of PaO2 by postconditioning with a volatile anesthetic in an in 
vivo model of ALI has not yet been described in the literature.  
A possible explanation for the deteriorated PaO2/FiO2 ratio could be an inhibition of 
the hypoxic pulmonary vasoconstriction (HPV) by both anesthetics. Clinical investigations 
are not conclusive concerning the possible effect of anesthetics on HPV. In animals models, 
volatile anesthetics seem to inhibit HPV, and increase intrapulmonary shunt fraction or reduce 
arterial oxygen tension in a dose–response manner 15,23,24, while propofol does not affect HPV 
25. In the clinical scenario, however, in patients undergoing one-lung-ventilation, sevoflurane 
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and propofol have been shown to have similar effects on shunt fraction and arterial oxygen 
tension 26,27. In our model, the impact of the volatile anesthetic-induced inhibition of HPV 
cannot be excluded. 
Second, we the expression of CINC-1 and MCP-1 was studied. These 
chemoattractants have been shown to possess potent chemotactic activity for neutrophils 
(CINC-1, MCP-1) and monocytes (MCP-1), and therefore play a significant role in the acute 
inflammatory response in ALI 28-31. The decrease of CINC-1 and MCP-1 proteins in BAL and 
of the mRNA in lung tissue by postconditioning with sevoflurane on the molecular level 
suggests a functional attenuation of inflammation by reduction of effector cell recruitment. In 
fact, we were able to prove this reduction of effector cells in the BALF (total cell count).  
Third, alveolar albumin and protein influx as markers of increased influx of 
inflammatory proteins and alveolo-capillary leakage, respectively, were evaluated. Lung 
hyperpermeability causing pulmonary edema is thought to be a main mechanism inducing 
ARDS 5,32.  Again, postconditioning with sevoflurane significantly decreased albumin and 
protein influx. Recently, it was shown that reduction of lung hyperpermeability protects 
against lipopolysaccharide-induced lung injury 33. Thus the therapeutic effects of sevoflurane 
on ALI could be mediated by reduction of lung hyperpermeability.  
Fourth, SP-B RNA expression in lung tissue was significantly less decreased upon 
injury in the sevoflurane compared to the propofol group, indicating a milder degree of injury. 
SP-B plays a critical role for maintenance of stability of surfactant. As shown in previous 
experimental approaches expression of SP-B is decreased upon injury, probably as a 
consequence of destruction of the alveolo-capillary unit with alveolar epithelial type II cells 
34,35. 
Fifth, lipopolysaccharide-propofol animals showed a significant higher expression of 
phospholipids in BALF. We hypothesize that increases in phospholipids in the alveolar space 
could be due to decreases in surfactant clearance by type II cells and the cells resident in the 
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alveolar space. Summarized, both results regarding SP-B and phsopholipids underline a less 
deteriorated surfactant function by postconditioning with sevoflurane compared to propofol 
after lipopolysaccharide challenge36.   
Up to now, several in vivo studies have explored the effects of sevoflurane on lung 
tissue but with inconsistent results. Takala et al. compared sevoflurane anesthesia with 
thiopentone anesthesia in a model of ventilated healthy pigs. It was demonstrated that alveolar 
epithelial cell (AEC) type II cell integrity and ultrastructure remained unchanged after long-
term (6 hours) high concentration exposure to sevoflurane (1.5 MAC) 37. Furthermore, a 
lower gene expression of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) was 
detectable in the intact porcine lung tissue after sevoflurane anesthesia 38. On the other hand 
an increase of pulmonary inflammatory mediators and pulmonary NO3- and NO2- production 
after sevoflurane anesthesia was revealed by another study using the same model 39. However, 
this model did not use an ALI model. Additionally, the sevoflurane concentration of 4 Vol. % 
was rather high compared to our model.  
To exclude a negative effect of propofol cremophor on pulmonary cells, we performed 
in vitro experiments. RPAEC were co-exposed to propofol in concentrations previously 
reported 40,41. No increased cytotoxicty or enhanced inflammatory response could be 
observed. Additionally, it has to be mentioned that several studies have pointed out a 
protective effect of propofol as well 42-44. 
Another component, which theoretically could enhance inflammatory injury, is the 
increased content of CO2 after 6 hours of injury. We discussed this increase as a consequence 
of injury. In vitro experiments underlined our hypothesis by showing that increased 
concentrations of CO2 did not interfere with the inflammatory reaction. This is in accordance 
with the literature, where only CO2 values of 15% or 20% induced an additional injury 45. 
Only few reports exist focusing on the postconditioning capabilities of sevoflurane in 
acute lung injury. In a recent publication, Hofstetter et al. examined the antiinflammatory 
 17
effects of sevoflurane in an in vivo model of lipopolysaccharide-induced endotoxemia in rats. 
In this study administration of sevoflurane 15 min after stimulation with lipopolysaccharide 
resulted in a decrease of TNF-α and Il-1β plasma levels 46. In contrast to our study, 
lipopolysaccharide was given intravenously with an early administration of sevoflurane after 
the injury. In the present study, we were able to show antiinflammatory effects of sevoflurane 
even when administered 2 hours after a lipopolysaccharide-stimulation, i.e. with late initiation 
of postconditioning. This may be of clinical relevance for patients who have already suffered 
from a trigger event that may result in ALI, or even ARDS in that sevoflurane may 
beneficially interfere with the further development of the lung injury.  
In this study, we focused on the difference between the intravenous anesthetic 
propofol and the volatile anesthetic sevoflurane. However, it remains questionable if the 
observed difference would also be found with other intravenous anesthetics. Interestingly, in 
the cardiac ischemia-reperfusion injury, protection by volatile anesthetics, morphine and 
propofol is relatively well investigated 47. It is generally agreed that these agents reduce the 
myocardial damage caused by ischemia and reperfusion. Other anesthetics, which are often 
used in clinical practice, such as fentanyl, ketamine, barbiturates and benzodiazepines have 
been much less studied, and their potential as cardioprotectors is currently unknown. 
Therefore, general conclusions should not be drawn. 
Today, sedation of patient with ALI/ARDS in the ICU is commonly performed using 
propofol. In the last years, the antiinflammatory effects of this intravenous anesthetic have 
been extensively studied in several in vivo studies. It has been shown that propofol has 
antiinflammatory effects that attenuate cytokine response following endotoxin shock in rats 
48,49. Several studies suggest that pre-treatment and post-treatment with propofol provides 
protective effects in endotoxin-induced ALI 19,50 and lipopolysaccharide-induced shock 51. 
However, the antiinflammatory effects of propofol are thought to be at least in part due to 
containing EDTA, which is a component of the commercially used propofol formulation 52. In 
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our study, we used a propofol formulation in 14% Cremophor without EDTA as clinically 
used propofol would induce hypervolemia in rats due to the low concentration of propofol. 
This could explain why less antiinflammatory effects in the propofol groups were found. 
However, a recent clinical trial, comparing the antiinflammatory property of sevoflurane and 
propofol in patients undergoing thoracic surgery with one-lung ventilation has also shown less 
inflammatory response in the sevoflurane group, even in the presence of EDTA 53.  
Since the AnaConDa was approved for the use in ICU’s, it is now possible to take 
advantage of the properties of volatile anesthetics like fast induction, fast awakening and easy 
titration for sedation of postoperative and critically ill patients. Only few studies have 
assessed the use of volatile anesthetics especially sevoflurane via AnaConDa in ICU patients 
so far 6,54.  Recently, a significantly shorter recovery time and a significantly shorter 
hospitalization time with a sevoflurane sedation compared to propofol was demonstrated in 
patients after cardiothoracic surgery 54. Up to now there are no clinical studies regarding the 
effects of sevoflurane sedation in patients with ALI or ARDS. The results of this in vivo study 
indicate that a sevoflurane sedation of patients with ALI may be beneficial. 
Our study has several limitations. First, as already discussed, we used a special 
formulation of propofol in 14% cremophor without EDTA, which is not commonly used in 
the ICU. This could be a reason for the reduced immune response in the propofol group. In 
addition, findings of this study could be specific to this animal model. However, the 
lipopolysaccharide injection model has recently been evaluated to promise the most direct 
clinical relevance considering gram-negative sepsis in which ALI is most common 55,56. 
Second, our observations are based on a model of a beginning ALI and therefore may not be 
applicable in already established ARDS. Moreover, we studied the effect of sevoflurane only 
during a very short period (6 hours) compared to the clinical situation. In addition we 
administered a FiO2 of 1.0 in our model which is not commonly used on ICUs except for 
severe cases of ARDS. To our knowledge nothing is known about any interaction of 
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hyperoxia and sevoflurane that may influence the antiinflammatory effects of sevoflurane. 
According to the literature hyperoxia-induced toxic effects on cells appear only after exposure 
times of more than 12 hours 57. Despite we cannot exclude that the hyperoxia influences the 
anitiinflammatory effects of sevoflurane in our model. 
In spite of these limitations, this study might be of clinical relevance.  We could show 
that in developing ARDS gas exchange deteriorates significantly less by just using 
sevoflurane as sedative compared to propofol. This property of sevoflurane seems to be 
mediated due to inhibition of lung inflammation as indicated by lower levels of cytokines and 
less recruitment of effector cells into the lung tissue. Sedating ICU patients with sevoflurane   
using the AnaConDa system might therefore be a new promising therapeutic approach for 
ALI and ARDS. Moreover, the application of sevoflurane can be easily combined with 
protective ventilation strategies generating further interesting treatment options.  
In conclusion, the present study indicates that anesthetic postconditioning with 
sevoflurane offers beneficial properties compared to propofol in a model of ALI in vivo. 
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